RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyFox,
In corporate mergers or takeovers, or in finance in general, creating a new class of non trading shares has often occurred although I cannot cite cases. I go on discussions with my corporate lawyer friends. I have also heard of big pharma taking a minority interest within a partnership, and then doing a buyout after more information is available that can serve as the basis for the final price.
The line of reasoning I outlined has this flaw which could be raised by naysayers: why would big pharma pay $1.5 bil for a third of the company when the market cap is one tenth that. The answer would be: competitive pressures, and the right to be our exclusive partner and design our trials. It also would lead to a conditional buy out based on a pre agreed price dependent on future results, reducing uncertainty for all parties.
Win win win.
Like I said, that is my dream, not based on anything I have heard from ONCY.